BPC-157: Identity, the Preclinical Record and the Limits of the Evidence

Evidence at a glance

Preclinical only

BPC-157 is one of the most studied repair peptides in animal research. Everything below comes from cell culture and rodent models. No controlled human trial has been published.

Why researchers are interested

It survives stomach acid, where most peptides break down. The research also points at the repair process itself, meaning new blood vessel growth and fibroblast migration, rather than at covering up a symptom. That combination is why it became so heavily studied in soft tissue models.

What the research found

• Faster tendon healingRodent tendon studies reported quicker functional recovery in treated animals than in controls
• Tendon cell growth in cultureIncreased fibroblast outgrowth, survival and migration (Chang, 2011)
• Protection of the gut liningLess mucosal damage across gastric and intestinal injury models (Sikiric, 2011)
• New blood vessel formationIncreased angiogenesis at healing sites in muscle and tendon (Seiwerth, 2010)

Reported in the literature

• No controlled human safety data has been published, so there is no trial from which an adverse effect rate could be quoted.
• Animal studies at the doses used report no consistent toxicity, but formal toxicology has not been published.
• Not approved by any medicines regulator for any use.
• Prohibited in competitive sport at all times under the WADA Prohibited List.

Findings are summarised from the sources listed under References on this page, and from approved product labelling where a compound has one. These are outcomes observed in published studies, not effects claimed for any person, and nothing here is a recommendation for human use.

← All research guides

BPC-157 is one of the most-studied peptides in the research community and one of the most misrepresented. This guide covers its identity, what the published literature actually examined, the mechanisms still under investigation, and the limits of the evidence base. It is written for researchers and is not medical guidance.

What BPC-157 is

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids. Its sequence derives from a partial sequence of a protein called Body Protection Compound, originally identified in human gastric juice.

• CAS 137525-51-0 (PubChem CID 9941957)
• Molecular formula C₆₂H₉₈N₁₆O₂₂
• Molar mass 1419.5 g/mol
• Length 15 residues

Verified against PubChem on 2 October 2026.

A defining property noted across the literature is stability: it remains intact in aqueous solution and in gastric environments where many peptides degrade. That stability is a large part of why it became a frequent subject of preclinical work — it survives experimental conditions that would destroy a less robust sequence.

Research-use note: BPC-157 is a research chemical. It is not an approved drug or supplement, and the findings below come exclusively from cell-culture and animal-model studies. Nothing here describes or implies use in people.

What the published literature covers

The BPC-157 record is overwhelmingly preclinical: in-vitro cell culture and in-vivo rodent models. Four areas carry most of the citations.

• Soft-tissue and tendon research. Chang et al. (Journal of Applied Physiology, 2011) examined effects on tendon-derived fibroblast outgrowth, survival and migration in cultured cells.
• Gastrointestinal research. The earliest and largest body of work, reviewed by Sikiric and colleagues (Current Pharmaceutical Design, 2011), studied BPC-157 in models of gastric and intestinal mucosal injury. Given the compound’s origin in gastric juice, this is where the literature began.
• Angiogenesis research. Brcic and colleagues (Journal of Physiology and Pharmacology, 2009) investigated its relationship to blood-vessel formation during muscle and tendon healing in animal models.
• Musculoskeletal soft tissue. Gwyer, Wragg and Wilson (Cell and Tissue Research, 2019) consolidated animal-model findings on muscle, ligament and connective-tissue healing.

The shape of the evidence base

This section matters more than any individual result, and it is the part most summaries leave out.

A large share of the BPC-157 literature originates from a small number of closely associated research groups, much of it in rodent models, and a substantial portion in a narrow set of journals. That is not a claim that the work is wrong. It is a statement about concentration: findings that have not been widely reproduced by independent groups carry less weight than findings that have, and the distinction is invisible if you only read citation counts.

There is also no substantial published human clinical-trial literature. Anyone citing BPC-157 should be precise that the evidence is animal and cell-culture work, because secondary sources routinely describe rodent results in language that implies human outcomes.

Mechanisms under investigation

Researchers have proposed several mechanisms to account for effects observed in animal models:

• Modulation of growth-factor signalling during tissue repair.
• Interaction with the nitric-oxide (NO) pathway, which is involved in vascular tone and blood flow.
• Association with VEGFR2, a receptor central to blood-vessel formation, in angiogenesis studies.
• Influence on collagen organisation during tissue-repair models.

These are active areas of investigation, not settled conclusions. A proposed mechanism in a rodent model is a hypothesis about how an observed effect might work, not an established pathway.

Form, reconstitution and storage

BPC-157 is supplied as a lyophilized powder. Standard laboratory practice is to reconstitute with bacteriostatic water, swirl rather than shake until dissolved, and store the reconstituted solution refrigerated at 2–8 °C. The lyophilized powder is kept frozen and protected from light, and repeated freeze-thaw cycles are avoided. Our walkthrough covers the general procedure: how to reconstitute peptides.

(General lab-handling notes, not usage instructions, and no substitute for the protocol in force in the receiving laboratory.)

For research use only

All products and information referenced here are intended strictly for laboratory and scientific research use only. They are not for human or animal consumption and are not drugs, foods, supplements, or medical devices. Nothing here should be interpreted as medical advice or as describing safe or effective use in people. Products are supplied against a stated purity specification.

Explore BPC-157 and related research peptides

• BPC-157 10 mg — specifications and stated purity
• Wolverine Stack (BPC-157 + TB-500)
• KLOW 80 mg — four-peptide blend including BPC-157
• BPC-157 vs TB-500 — how the two compare
• Full research catalog

Common questions about BPC-157

What does BPC stand for?

Body Protection Compound. BPC-157 is a synthetic 15-amino-acid peptide whose sequence is derived from a protein first identified in human gastric juice.

Has BPC-157 been tested in humans?

No controlled human trial has been published. The research record is cell culture and animal models, and BPC-157 is not approved by any medicines regulator.

What is the difference between BPC-157 and TB-500?

They are different molecules studied along different pathways. Our BPC-157 vs TB-500 comparison sets them side by side, and the Wolverine Stack combines both.

References

1. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PubMed
2. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. PubMed
3. Brcic L, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009. PubMed
4. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011. PubMed
5. Compound identity verified against the PubChem database, retrieved 2 October 2026. PubChem